Array BioPharma’s new colorectal cancer treatment gains breakthrough therapy designation from FDA
Array BioPharma has achieved a significant regulatory milestone as its innovative combination therapy for metastatic colorectal cancer (mCRC) has been granted breakthrough therapy designation by the U.S. Food and Drug Administration (FDA). The designation specifically targets the treatment regimen combining encorafenib (BRAFTOVI), binimetinib (MEKTOVI), and cetuximab for mCRC patients with the BRAFV600E mutation, following the […]